Viewing StudyNCT02508467

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 7:17 AM
Last Modification Date: 2024-10-26 @ 11:47 AM
Study NCT ID: NCT02508467
Status: COMPLETED
Last Update Posted: 2024-04-12
First Post: 2015-07-09
Brief Title: A Phase 1 Study of Fisogatinib BLU-554 in Patients With Hepatocellular Carcinoma
Sponsor: Blueprint Medicines Corporation
Organization: Blueprint Medicines Corporation
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Hepatocellular Carcinoma HCC
Keywords:
Name View
Liver Neoplasms View
Liver cancer View
FGF19 gene amplification View
FGF19 overexpression View
FGF19 upregulation View
Cyclin D1 CCND1 gene amplification View
Cyclin D1 CCND1 copy number gain View
BLU-554 View
FGFR4 View
Hepatocellular carcinoma View
Liver Disease View